Neibla Priego
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neibla Priego has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Manuel Valiente
Spanish National Cancer Research Centre Madrid Spain
61 shared publications - Carolina Hernández-Oliver
Brain Metastasis Group Spanish National Cancer Research Centre (CNIO) Madrid Spain
60 shared publications - Ana de Pablos-Aragoneses
Spanish National Cancer Research Centre New York, NY United States
59 shared publications - Fatima Al-Shahrour
Bioinformatics Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain
59 shared publications - Laura Álvaro-Espinosa
Spanish National Cancer Research Centre Madrid Spain
59 shared publications - María Perea-García
Spanish National Cancer Research Centre Madrid Spain
59 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Wiley in Molecular Oncology
- Vol. 20 (8) , 1895-1904
Astrocyte heterogeneity in brain metastases
Brain metastasis is increasingly understood as a disease of reciprocal adaptation between metastatic cells and the brain microenvironment. Among host cells, astrocytes have emerged as central regulators of metastatic colonization, survival, immune remodeling, and treatment resistance. Recent studies are re‐defining astrocytes to explore the functional implications of their cellular heterogeneity. Evidence in brain metastasis indicates that astrocyte responses are heterogeneous across anatomical space, stage of colonization, and tumor type. This framework helps explaining how distinct astrocyte programs can coexist and why no single experimental platform captures their organization and complex biology. Moving toward spatially resolved, longitudinal, and functionally validated definitions of astrocyte states could clarify mechanisms and guide more precise therapeutic opportunities in brain metastasis. In this Viewpoint, we examine studies that have challenged the long‐standing paradigm of astrocytes as a uniform entity, highlighting how recent technological advances reinforce previous findings and pave the way for identifying new therapeutic targets.
- 8 July 2026
- Published by Wiley in Molecular Oncology
- Vol. 20 (8) , 1895-1904
Open AccessAstrocyte heterogeneity in brain metastases
Brain metastasis is increasingly understood as a disease of reciprocal adaptation between metastatic cells and the brain microenvironment. Among host cells, astrocytes have emerged as central regulators of metastatic colonization, survival, immune remodeling, and treatment resistance. Recent studies are re‐defining astrocytes to explore the functional implications of their cellular heterogeneity. Evidence in brain metastasis indicates that astrocyte responses are heterogeneous across anatomical space, stage of colonization, and tumor type. This framework helps explaining how distinct astrocyte programs can coexist and why no single experimental platform captures their organization and complex biology. Moving toward spatially resolved, longitudinal, and functionally validated definitions of astrocyte states could clarify mechanisms and guide more precise therapeutic opportunities in brain metastasis. In this Viewpoint, we examine studies that have challenged the long‐standing paradigm of astrocytes as a uniform entity, highlighting how recent technological advances reinforce previous findings and pave the way for identifying new therapeutic targets.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Survival analysis of the 37-gene signature derived from CD74+ microglia/macrophages across TCGA primary tumors cohorts
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Survival analysis of the 37-gene signature derived from CD74+ microglia/macrophages across TCGA primary tumors cohorts
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces PD-L1 expression in CD74+ from patient-derived organotypic cultures
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces PD-L1 expression in CD74+ from patient-derived organotypic cultures
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 14 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Patient-derived organotypic cultures (PDOC) treated with Ibudilast
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 14 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Patient-derived organotypic cultures (PDOC) treated with Ibudilast
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces brain metastasis in vivo without comprising the viability of cancer cells in vitro
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces brain metastasis in vivo without comprising the viability of cancer cells in vitro
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reverts the protumorigenic signature of CD74+ microglia/macrophages in vivo
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reverts the protumorigenic signature of CD74+ microglia/macrophages in vivo
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 9 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Gene set enrichment analysis of CD74+ microglia/macrophages
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 9 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Gene set enrichment analysis of CD74+ microglia/macrophages
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
List of marker genes defining each CD45⁺ immune cell population identified by single-cell RNA-seq
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
List of marker genes defining each CD45⁺ immune cell population identified by single-cell RNA-seq
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
List of flow cytometry antibodies
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
List of flow cytometry antibodies
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
CD74+ cells are mainly BMDM with transcriptional enrichment in OXPHOS pathway
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
CD74+ cells are mainly BMDM with transcriptional enrichment in OXPHOS pathway